Osimertinib May Improve Outcomes in EGFR Mutation-Postive NSCLC
Grade 3 or higher adverse events were less frequent with osimertinib.
HealthDay News — For patients with previously untreated, epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC), treatment with osimertinib is associated with longer progression-free survival than a standard EGFR tyrosine kinase inhibitor (TKI), according to a study published in the New England Journal of Medicine to coincide with the European Society for Medical Oncology Asia 2017 Congress, held from November 17 to 19 in Singapore.
Jean-Charles Soria, MD, PhD, from the Gustave Roussy Cancer Campus and University Paris-Sud, and colleagues conducted a phase 3 trial involving 556 patients with previously untreated EGFR mutation-positive advanced NSCLC. Participants were randomized to receive osimertinib or standard EGFR-TKI.
The researchers found that median progression-free survival was significantly longer with osimertinib than EGFR-TKIs (18.9 months vs 10.2 months; hazard ratio for disease progression or death, 0.46 [95% confidence interval, 0.37 to 0.57; P <.001]). The 2 groups had a similar objective response rate (80% and 76%, respectively; odds ratio, 1.27 [95% confidence interval, 0.85 to 1.90; P =.24]). The median response duration was 17.2 months with osimertinib and 8.5 months with standard EGFR-TKIs. Grade 3 or higher adverse events were less frequent with osimertinib (34% vs 45%).
"Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events," the authors write.
The study was funded by AstraZeneca, the manufacturer of osimertinib.
Soria JC, Ohe Y, Vansteenkiste, J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer [published online November 18, 2017.] NEJM. doi: 10.1056/NEJMoa1713137